Efficacy, Safety Profiles and Cost-effectiveness Analysis of Pegfilgrastim and Lenograstim in Patients with Non Metastatic Breast Cancer Receiving Adjuvant Myelosuppressive Chemotherapy

Trial Profile

Efficacy, Safety Profiles and Cost-effectiveness Analysis of Pegfilgrastim and Lenograstim in Patients with Non Metastatic Breast Cancer Receiving Adjuvant Myelosuppressive Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2012

At a glance

  • Drugs Pegfilgrastim (Primary) ; Lenograstim
  • Indications Febrile neutropenia; Neutropenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2012 New trial record
    • 24 Mar 2012 To date 20 patients have been enrolled
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top